India’s Aurobindo buys Sandoz US assets from Novartis
The transaction underpins Novartis's strategy of achieving sustainable and profitable growth in the US in the long term.
Keystone
Swiss pharmaceutical company Novartis announced the divestment of its dermatology and generic tablet portfolios of Sandoz US to India’s Aurobindo Pharma for a $900 million (CHF870 million) cash payment.
This content was published on
2 minutes
A possible performance-related payment of $100 million could be added to the purchase price, the Swiss AWP financial news agency reported.
The divested business generated sales of $600 million in the first half of 2018. It includes approximately 300 products and development projects.
A Novartis spokesman refused to comment on whether other parts of the Sandoz portfolio in the United States were still for sale.
750 employees affected
The production facilities in Wilson, North Carolina, as well as in Hicksville and Melville, New York, will also be transferred to Aurobindo.
In this context, approximately 750 employees and the sales force of the dermatology business PharmaDerm will be transferred to the Indian company upon completion of the transaction.
Novartis said the transaction is expected to close during 2019.
Focus on complex generics
Sandoz will focus instead on complex generics, value-added medicines and biosimilars.
The transaction underpins Novartis’s strategy of achieving sustainable and profitable growth in the US in the long term. “With this transaction, we are focusing our business,” Sandoz CEO Richard Francis was quoted as saying.
The Sandoz portfolio will remain “strong” even after the transaction, according to the company statement. It includes injectables, respiratory products and ophthalmics.
This content was published on
The cantonal parliament of Vaud has approved a loan of CHF9.5 million ($11.5 million) for Château de Chillon, the most-visited monument in Switzerland.
Swiss party president Thierry Burkart to step down in October
This content was published on
Thierry Burkart, president of the centre-right Radical-Liberal Party, wants to hand over the presidency in October, around two years before the next national elections.
Climate Alliance presents action plan on 20th anniversary
This content was published on
The Swiss Climate Alliance has presented an action plan showing how Switzerland could make a success of the energy transition and achieve a net zero balance within ten years.
Swiss business group expects export slump after strong start to year
This content was published on
The Swiss economy was still robust in the first quarter of 2025 but is coming under increasing pressure, says the Swiss business federation, economiesuisse.
Five arrested in Switzerland in human-trafficking raid
This content was published on
Law enforcement authorities in Switzerland and Romania have busted a human trafficking ring. They arrested a total of 17 suspects.
OECD significantly lowers Swiss GDP forecast due to Trump
This content was published on
The Swiss economy is likely to grow more slowly in 2025 and 2026 than previously assumed, according to the OECD economic organisation.
UBS economists more confident about Swiss economy in 2025
This content was published on
UBS economists have revised upwards their estimates of Swiss GDP growth for the current year. However, they are more pessimistic for next year, due to the spectre of US tariffs.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis chief hints at job cuts in Switzerland
This content was published on
The president of pharmaceutical giant Novartis has announced job cuts in an interview with Swiss newspaper NZZ am Sonntag.
This content was published on
The expansion will take place at the company’s Stein site in Aargau. As a first step, Novartis plans to create 260 new jobs and says there is potential to raise that number to 450 by 2021. Last year the company announced plans to slash 500 jobs at its Basel headquarters, but said at the time…
Eye on the Multinationals: Your questions become our stories
This content was published on
Do you work for or would like to work for a multinational company? Are you concerned about the impact of multinational companies at home and abroad?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.